Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...

Aducanumab – which Biogen is developing with Japanese drugmaker Eisai – was all but abandoned in 2019 after the partners decided that two phase 3 trials of the drug were unlikely to show an ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come ...

Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...

Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

A US university has launched a prevention trial examining the use of Eli Lilly’s investigational remternetug in young adults to prevent further development of Alzheimer’s disease. Washington ...

Biogen Pharmachem Industries Ltd share price was down by -0.86% from the previous closing price of ₹1.16. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...